FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison

• DOI: 10.21873/cdp.10303
• Publication Date: 2024-05-09T08:00:31Z
• Authors: ELENA ORLANDI; CHIARA CITTERIO; ELISA ANSELMI; LUIGI CAVANNA; STEFANO VECCHIA
• Keywords: FOLFIRINOX

Advanced pancreatic cancer has a poor prognosis and 5-year survival rate <5%; thus, treatment of patients with advanced unresectable or metastatic disease is challenging. Current guidelines recommend either gemcitabine plus nab-paclitaxel (GnP) FOLFIRINOX (FOL) as first-line treatment. Data on both efficacy toxicity FOL versus GnP in are limited. This study aimed to compare the two chemotherapy regimens terms real-world setting.